Penumbra Inc (PEN)
About Penumbra Inc
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $1.4B
- Net income
- $177.7M
- Total assets
- $1.8B
- Market cap
- $12.6B
- Gross margin
- 67.1%
- Operating margin
- 13.5%
- Net margin
- 12.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.4B
- Cost of revenue
- $461.2M
- Gross profit
- $942.4M
- Operating expenses
- $753.2M
- Operating income
- $189.2M
- Income tax
- $27.4M
- Net income
- $177.7M
- EPS (basic)
- $4.57
- EPS (diluted)
- $4.52
Balance sheet
- Total assets
- $1.8B
- Current assets
- $1.2B
- Total liabilities
- $398.9M
- Current liabilities
- $183.1M
- Shareholders’ equity
- $1.4B
Cash flow
- Operating cash flow
- $238.7M
- Investing cash flow
- -$404.6M
- Financing cash flow
- $26.5M
- Net cash flow
- -$137.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $12.6B
- P/E ratio
- 70.5
- EPS (diluted)
- $4.52
- Shares outstanding
- 39.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 18, 2015
Penumbra Inc (PEN) Stock Price
- Profitable — net income of $177.7M in FY2025.
- Revenue grew 88% from FY2021 to FY2025.
- Gross margin of 67.1%, net margin 12.7%.
- Trading 11% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 70.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Penumbra Inc.
Write a review
News about Penumbra Inc
News & sentiment via Polygon.io
Penumbra Inc: frequently asked questions
Is Penumbra Inc an American company?
Yes — Penumbra Inc is an American company headquartered in Alameda, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Penumbra Inc headquartered?
Penumbra Inc is headquartered in Alameda, California, United States.
Is Penumbra Inc publicly traded?
Yes — Penumbra Inc is a publicly traded company. Its stock trades under the ticker symbol PEN on the NYSE.
What does Penumbra Inc do?
Penumbra Inc is an American Medical Devices company in the Health & Beauty sector.
